Section 1Global Biologic Market and Market Access
Lecture 1Introduction to Biopharmaceuticals and Biopharmaceutical Market
Lecture 2Classification of Biopharmaceutical
Lecture 3Chemical Drugs Vs. Biologic Drugs
Lecture 4Principle of Naming of Biologics
Lecture 5Global Biopharma Market Overview – Product, Application & Regional Dynamics
Lecture 6Classes of Biologics – Comprehensive Classification & Subclasses
Lecture 7Global Biopharmaceutical Market | Market Size | Growth | Regional Shares| Top Therapy Areas | Innovation Pipeline
Lecture 8Global Biologic Market Trends
Lecture 9Introduction to Market Access | Objectives | Various Key Terminologies | Steps of Market Access | Understanding on Pricing and Reimbursement
Lecture 10Market Access Strategic Planning : Steps and Logical Sequencing for Market Access Strategy Development
Lecture 11Indication Sequencing | Indication Prioritization | Development of Indication Timeline | Indication Matrix | Value Based Indication Prioritization
Lecture 12Indication Prioritization Case Study
Lecture 13Market Access Value Dossier : What it is | Significance | Components | What to include
Lecture 14AMCP Market Access Dossier Preparation
Lecture 15Target product profile (TPP) | Quality Target product profile (QTPP) | Critical Quality Attributes (CQAs) | Quality By Design (QbD)
Lecture 16Practical Training on Value Dossier Preparation | Sample Value Dossier with each section with data | Key points to consider while preparing value dossier
Lecture 17Clinical Data in Value Dossier | Understanding in different types of clinical study with rationale | Case based example on clinical study section writing
Lecture 18Pipeline in a molecule | Case Study
Lecture 19Global Regulatory Agencies & Framework for Biologics (ICH + Regional Integration)
Lecture 20ICH Q5 Series & Q6B – Deep Dive into Biologic-Specific Guidelines
Lecture 21Biologic CMC Deep Dive – Cell Line, Upstream & Downstream Processing
Section 2Biopharmaceutical Classification and study on each class
Lecture 22Advanced Understanding on Structure of Monoclonal Antibody (MAB)
Lecture 23Monoclonal Antibodies Vs. Polyclonal Antibodies
Lecture 24Monoclonal Antibodies : Detailed Understanding
Lecture 25Simulation on MAB Structural Interpretation
Lecture 26Production of Monoclonal Antibodies
Lecture 27Structural Comparison of Adalimumab and Trastuzumab | Structural Influence on Therapeutic Targeting | Structural Engineering Example
Lecture 28Structural Comparison of Adalimumab and Trastuzumab | Structural Influence on Therapeutic Targeting | Structural Engineering Example
Lecture 29Trastuzumab – Structural Design and Therapeutic Outcome
Lecture 30Bevacizumab – Structural Design and Therapeutic Outcome
Lecture 31mAB - At a glance
Lecture 32Cytokine Know How - Explainer
Lecture 33Cytokines - Product Class Orientation
Lecture 34Vaccine Advanced Tech - Fundamental Understanding | Class Explainer
Lecture 35Recombinant protein
Lecture 36Synthetic Immunomodulators
Lecture 37Interferon
Lecture 38Erythropoiesis-stimulating agent
Lecture 39Blood Biologics Technology Understanding
Lecture 40ATMPs - at a glance
Lecture 41CAR-T Therapy | Different Types of CAR-T Therapy | Mechanism of action | Challenges | Brainstorming on Concept of Personalized Medicine | Understanding on marketed formulation
Lecture 42Live Biotherapeutic Products | LBPs | Class | Mechanism | Indication Positioning | Regulatory Requirements for LBPs
Lecture 43ATMPs | Types and Classification | Regulatory Mechanism
Lecture 44ATMPs - at a glance
Lecture 45ATMPs Deep Drive | ATMP Classification Framework | Manufacturing | CRISPR Gene Editing | Regulatory Requirements
Lecture 46LBP Strategy and RA Development | Manufacturing Process | CMC Requirements
Lecture 47Decoding Biologic Complexity
Lecture 48Biologic Class Documentation Guide | Modality Specific Checklists
Section 3Biopharmaceutical Regulatory Pathways | US Regulation
Lecture 49R&D Process & Introduction to discovery, development to commercialization process
Lecture 50Investigational New Drug Application (INDA)
Lecture 51New Drug Application (NDA)
Lecture 52 Biological Licensing Application (BLA)
Lecture 53Basic concept and understanding of the Generic Drug
Lecture 54Abbreviated New Drug Application (ANDA)
Lecture 55Abbreviated Biosimilar Application - 351(k): Advance Strategic Planning Process : Originator Vs. Biosimilar Development and Regulatory Approval Process | Reference Biologic | Purple Book | Data Requirements
Lecture 56505(j) ANDA, 505(b)(2) NDA, 505(b)(1) NDA
Lecture 57Purple Book: Significance | Searching | Assignments
Lecture 58Nomenclature of Biosimilars - How biosimilar names are built, why they matter, and what regulators expect
Lecture 59Biosimilar Naming – Examples & Principles
Lecture 60Vaccine development and approval Process
Lecture 61Clinical Trials Terminologies
Lecture 62Advance Learning on 505B2 Pathway
Lecture 63FDA Forms and How to fill the resources
Lecture 64Chemistry, Manufacturing & Controls
Lecture 65Strategic Discussion: PreIND, EOP1, EOP2 - What to expect !
Lecture 66Patent & Exclusivity - Strategic Understanding | Patent Restoration| Orphan Drug Exclusivity (ODE)
Lecture 67USFDA expedited programs for Pharmaceuticals and Biopharmaceuticals
Lecture 68Practical Queries on different USFDA application and Filing
Lecture 69REMS Strategic Planning
Lecture 70U.S. Biologic Regulatory Pathways and Market Access - Innovator Biologics + Biosimilars + Commercial Access Execution
Lecture 71Biologic CMC Review | Review Expectations
Section 4EU Regulation - Discovery Development to Commercialization
Lecture 72EU Regulatory System Fundamentals
Lecture 73Introduction to EU Regulation
Lecture 74Orientation to European Countries and National Regulatory Bodies
Lecture 75EMA and EMA Authorisation Process
Lecture 76EMA and EMA Authorisation Process
Lecture 77Centralised vs DCP vs MRP vs National Procedure - Detailed Strategic Insight
Lecture 78EU MA Application Types and Strategic Planning
Lecture 79EU MA Procedure - Centralised, Decentralised, Mutual Recognition, National Procedure
Lecture 80EU MA Strategic Planning: Full, Full-mixed, hybrid applications. Generic, Similar biologic application pathway, Well-established use application, Fixed combination application, Informed consent application
Lecture 81Validity of the EU MA - Renewal steps, Cessation of the marketing authorisation, Significance of "Placed in Union Market", Suspension or withdrawal & EU MA for licensed products
Lecture 82Structured Practical understanding of EU legal bases | Understanding Data Requirements
Lecture 83Practical understanding of EU legal bases for Marketing Authorisation Applications (MAA) | Decision Tree
Lecture 84Centralised Procedure Timetable and Review Logic
Lecture 85DCP / MRP / National Procedure – Practical Workflow Module
Lecture 86EU Procedures Critical Operational Steps - Validation • Clock-Stop • List of Questions • Approval • National Phase
Lecture 87DCP vs MRP Timeline
Lecture 88EU Adaptive Pathway
Lecture 89European public assessment report (EPAR) - Importance, Component, Management, Updation
Lecture 90SPOR - Concept of Master Data Management
Lecture 91The 'sunset clause' for marketing authorisation of pharmaceuticals
Lecture 92LoQ Response Strategy - EU Regulatory Procedures (CP / DCP / MRP) – Winning the Day 120 / Mid-Cycle Response
Lecture 93Response to list of Questions (LoQ)
Lecture 94Response to list of outstanding issues (LoOI) - Day 180 / Final Assessment Phase Response
Lecture 95Oral Explanation Training Module - CHMP / CMDh Oral Defence Strategy – From Data to Approval
Lecture 96CHMP - Question Bank Real-Life Regulatory Questions + Model Answers (CP / DCP / MRP)
Lecture 97Conditional marketing authorisation | Marketing authorisation under exceptional circumstances
Lecture 98Compassionate Use
Lecture 99EU Prime Designation
Lecture 100MHRA - UK Regulation
Lecture 101Summary of Product Characteristics
Lecture 102Drug Registration and Submission Strategic Planning for Russia and EAEU region
Lecture 103Accelerated assessment by EMEA
Lecture 104Certificate of Suitability (CEP) | Significance | Importance | Understanding Regulatory Compliance and Submission Process | Walkthrough
Lecture 105CEP Dossier DMF - Differences
Lecture 106Policy 0070 | RPDP Submission and Management timeline | Anonymisation Report (AnR) - Significance | AnR in FRDP
Lecture 107Comprehensive EU Clinical Trial Regulatory Affairs – CTA, CTIS, Strategy & Execution
Lecture 108CTIS Operating Model – Advanced EUClinical Trial Execution Module
Lecture 109CTA Structure: Part I / Part II (EU Clinical Trials Regulation)
Lecture 110Country-wise Part II Requirement Master
Lecture 111CTIS Hands-on Simulation Module Step-by-Step Clinical Trial Submission Exercise (CTR Execution Training)
Lecture 112EU CTR Advanced Module - Substantial Modifications, Safety Reporting, Transition Lessons & End-of-Trial Obligation
Lecture 113IMPD | Significance | Format of IMPD | Differences with CTA, IB, IND
Lecture 114Investigator’s Brochure | Significance | Format of IB | Preparing different sections of IB
Lecture 115Patent Landscape & Freedom to Operate (FTO) – EU Perspective - Strategic Regulatory + IP Integration Module (Drugs & Biologics)
Lecture 116EU Data Exclusivity, Market Protection & Orphan Exclusivity
Lecture 117Data Exclusivity and Market Protection - Supplementary Patent Protection, Exclusivity, 6/10 Rule, 8+2+1 Formulae
Lecture 118EU Orphan Medicinal Products Regulation
Lecture 119Paediatric use marketing authorisation (PUMA) & Paediatric Investigation Plan (PIP)
Lecture 120EU Supplementary Protection Certificates (SPC) & Paediatric Rewards
Lecture 121Patent vs Regulatory Exclusivity vs Trademark vs Launch Sequencing (EU Perspective)
Lecture 122“No EU-Style Patent Linkage” – What It Really Means (EU vs US)
Lecture 123EU vs US Regulatory–IP Framework
Lecture 124Global Patent + Exclusivity Timeline Dashboard - Executive-Level Strategic Tool (EU + US + Global Integration)
Lecture 125Full EU Submission Strategy Planner
Lecture 126CHMP Question Bank - Regulatory Questions (CP / DCP / MRP – EU Focus)
Lecture 127Biologics-Specific Question Bank - CHMP / CAT / PRAC-Style Questions
Lecture 128Biosimilar Road Map
Lecture 129ATMP Strategic Submission Pathways – EU vs US
Lecture 130Regulatory Submission Pathways – BLA, MAA & Global Filing Strategy
Section 5Innovation Management and Strategic Pathway for Biologic and Biosimilar
Lecture 131Introduction to Intellectual Property in Life Sciences | Types of IP | Introduction to Patent Portfolio Strategy
Lecture 132Global Pharmaceutical Patent Landscape | Strategic Overview of Global Patent Filing and Protection
Lecture 133Understanding on Patent System
Lecture 134Global Pharmaceutical Patent Filing Strategy
Lecture 135PCT Patent Filing Flow
Lecture 136Patentability Criteria in Pharmaceuticals | Practical Case Study
Lecture 137Patent Law Framework for Pharmaceuticals
Lecture 138Understanding and Decoding Section 3(d) of the Indian Patent Act | Case Based Analysis
Lecture 139Evergreening vs Genuine Innovation in Pharmaceutical Patents | Evergreening and Genuine Innovation Evaluation
Lecture 140Pharmaceutical Patent Lifecycle - Integrated Layer Strategy
Lecture 141Blockbuster Drug Patent Thicket Strategy
Lecture 142New Indication Approval Process and Promotion
Lecture 143Biosimilar Approval and Patent Management | Strategic Pathway of Patent Negotiation and Litigation in Biosimilar Approval | Patent Dance | FAQs on Biologic Patent Management
Lecture 144Biosimilar launch case study | Patent Dance Framework
Lecture 145Biosimilar Launch Framework
Lecture 146Biosimilar 180 Day Notice
Lecture 1473(A) List | Significance | Importance | How to interpret
Lecture 148Steps to win over innovator patents | Step wise planning
Lecture 149Biosimilar Launch Project Roadmap with defined stages of project
Lecture 150Timing of Biosimilar Submission and Approvals | Two Scenario based timeline assessments
Lecture 151Hands on Training on Reference Biologic Patent | Classify RPS Biologic Patents | Case Simulation
Lecture 152How to work on RPS’s Patent | Walkthrough | Case Study
Lecture 153Biosimilar Launch Project With Milestones
Lecture 154Analysis of Biologic Patents | Work Assignments
Lecture 155Biologic Patent Insight Worksheet
Lecture 156Patent Thickets | Concept | Implication | Case Based Learning
Lecture 157Understanding Patent Searching Process
Lecture 158IPC and CPC - Importance and Significance in Patent Search
Lecture 159IPC Structures for Pharmaceutical Patents
Lecture 160Freedom-to-Operate (FTO) | FTO Risk Assessment | Strategic Management
Lecture 161FTO Decision Tree – Generic Drug Launch Strategy
Lecture 162Fundamental of Pharmaceutical Patent Drafting | Structure | Component | Claim Anatomy | Effective Claim Writing
Lecture 163Pharmaceutical Patent Risk Management Framework
Lecture 164Patent Claim Coverage - Practical Example
Lecture 165Pharmaceutical Patent Filing Procedure and Global Filing Strategy | PCT Filing | Timeline
Lecture 166Advanced Understanding on Patent Opposition and Patent Litigation in Pharmaceutical Domain
Lecture 167Patent Prosecution and Handling Examiner Objections
Lecture 168Pharmaceutical Patent Portfolio Management | How to build and manage pharma patent portfolio
Lecture 169Pharmaceutical Patent Valuation and Licensing
Section 6Bio-manufacturing | Biosimilar Development | CMC requirements
Lecture 170Biosimilar Development Process
Lecture 171Strategic Consideration for Biosimilar Development
Lecture 172Regulatory Requirements for Biosimilar | Stepwise evidence based development | Analytical Similarity | Clinical Study | PKPD study requirements | CMC expectation of Biosimilar
Lecture 173Bio-Manufacturing Process Information
Lecture 174Biologic Lifecycle and CMC Submission Core Philosophy
Lecture 175Studies required for approval of biosimilar
Lecture 176Demonstrating Biosimilarity: A More Complex Task
Lecture 177Comparability of Biologics | Different Categories of Comparability | General Principles
Lecture 178Immunogenicity Assessment & Risk Management in Biologics
Lecture 179Immunogenicity In Biologics - Regulatory Strategy, Risk Assessment & CMC Writing Integration
Lecture 180Immunogenicity Case Studies
Lecture 181Immunogenicity Capstone Simulation - CMC immunogenicity justification | Control strategy update | QOS summary
Lecture 182Immunogenicity Advanced Case Writing
Lecture 183Download End-To-End Immunogenicity Case Simulation Workbook
Lecture 184Immunogenicity + ADA assay + Risk matrix
Lecture 185Master Module: Biologic Comparability - Process Changes, Biosimilarity & Regulatory Justification Framework
Lecture 186Biologic Comparability Protocol Template - Process Change / Post-Approval Change / Scale-Up / Site Transfer
Lecture 187Critical Quality Attributes (CQAs) & Critical Process Parameters (CPPs)
Lecture 188Analytical Characterization of Biologics (Structure, Purity, Potency)
Lecture 189Non-Clinical Development of Biologics: ICH S6 Requirements, Study Design & Regulatory Strategy
Lecture 190Clinical Development Strategy for Biologics: Phase I–III Design, Adaptive Trials & Regulatory Alignment
Lecture 191CQAs & CPPs in Biologics – Practical Case-Based Workbook
Lecture 192Stability Studies for Biologics (ICH Q5C + Real-Time Strategy)
Lecture 193ICH Q5C Guideline
Lecture 194Biologic Dossier Evaluation Explainer
Lecture 195Mastering Fermentation and Bioreactors Process Documentations
Lecture 196Justifying Fermentation Variances
Section 7 Submission Dossier | Publishing | Biologic CMC Review
Lecture 197Introduction to Common Technical Document (CTD)
Lecture 198CMC Dossier & Compliance Management
Lecture 199Fundamental of CMC | Detailed understanding of CMC section writing | Important Points regarding CMC | Drug Product and Drug Substance | Excipient, FP, Analysis and Stability Study Requirements
Lecture 200CMC Dossier & Compliance Management
Lecture 201Introduction to Electronic Common Technical Document (ECTD)
Lecture 202Advance Practical Training on Dossier Preparation focusing on drug registration in export countries
Lecture 203Importance of effective dossier management
Lecture 204Discussion on 85 common deficiencies in CTD submission dossier
Lecture 205Certificate of Analysis
Lecture 206Detailed Understanding on ANDA Submission Dossier
Lecture 207Prior Approval Submission
Lecture 208Regulatory Requirements for Biosimilar | Stepwise evidence based development | Analytical Similarity | Clinical Study | PKPD study requirements | CMC expectation of Biosimilar
Lecture 209CMC Writing Case Study | Successful Documentation
Lecture 210Structure for CMC Writing | Understanding 3.2.S and 3.2.P section | Documents requirements | Case Study
Lecture 211Well written Vs. Poorly Written CMC Section | Practical Example
Lecture 212Drug Substance Section in CMC | Documentations | Practical Examples | Do’s and Don’ts
Lecture 213Example of Well-Written Drug Substance Characterization | Impurities and Degradation Products | Well-Written Impurities and Degradation Products | Synthesis and Manufacturing Processes | Control of Drug Substance (Specifications, Testing, and Acceptance Criteria)
Lecture 214Stability Studies and Data Presentation in CMC Writing | Case Based Analysis of Stability Study Data Presentation | Interpretation of stability data
Lecture 215Developing Specifications for a New API
Lecture 216Example of Manufacturing Process and Controls
Lecture 217Interpretation of Stability Table
Lecture 218Critical Stability Scenarios | 8 Different Case Studies | Stability Study - Outcome based action plan creation
Lecture 219Common Pitfalls in CMC Writing and How to Avoid Them | Case Study
Lecture 220Grouped Submission | Significance | Importance in Market Access and Regulatory point of view | Case Study
Lecture 221Process Validation Report (PVR) | Sample Process Validation Report Analysis | CPPs and CQAs identification
Lecture 222Case Study - Omissions of CPPs in PVR | Case insight, explanation, action plan | Correlations - CPPs - CQAs - IPCs
Lecture 223Biologic Lifecycle and CMC Submission Core Philosophy
Section 8Stability Study
Lecture 224Modules on Stability Study : Stability Study - Fundamental Understanding | Interchangebility | Reports | API & FPP Stability Study
Lecture 225Climatic Zone and Stability Study Conditions as per ICH Guidelines
Lecture 226Stability Zone Finder
Lecture 227Stability Studies Case Discussions
Lecture 228Case Study: Managing Stability Study for Zone IV countries
Lecture 229Accelerated and intermediate testing conditions
Lecture 230Long Term Stability Testing Requirements
Lecture 231Testing Frequency
Lecture 232Bracketing
Lecture 233Matrixing
Lecture 234Critical Stability Issues - Database | Implication | Action Plan
Lecture 235Stability Study Requirements for Biologics - Regulatory, Registration, Lifecycle & Control Strategy Module
Lecture 236Advanced Case Study - Stability Requirements - EU, U.S., and Other Regions – Detailed Regulatory Planning
Lecture 237Biologic Stability Requirement Study Decision-Making Pathways - Step-by-Step Regulatory Planning Framework
Lecture 238Stability Studies Case Discussions
Section 9Bioequivalence Study
Lecture 239PKPD in Drug Discovery | PK-PD trial | Understanding PKPD from regulatory perspective in drug approval process
Lecture 240Bioequivalence Study | Study design | Different types of BE Studies
Lecture 241Bioequivalence Study | Study design | Parallel Study | Crossover study design | Other alternative study designs | Blood Sampling Planning | Analyte | Bioanalytical Methods Validation | Statistical Model | Ln Transformation | Dose normalisation | Confidence interval acceptance criteria
Lecture 242Biopharmaceutical Classification System (BCS) | Types | Biowaivers | BCS tool for drug development and regulatory submission
Lecture 243Bioequivalence Study - Discussion - Timeline of stability study and bioequivalence study
Lecture 244Bioequivalence Study - Discussion - Dissolution Testing
Lecture 245Bioequivalence Study - Generic Approval and Additives Labeling Requirements
Lecture 246BA BE Study Design | Comparing different types of the study design
Lecture 2472wco Study Design | Design Table | Importance
Lecture 2483wco Study Design | Design Table | Importance
Lecture 249FRCO Study Design | Design Table | Importance
Lecture 250Parallel Vs. Crossover Study Design
Section 10Variation Management
Lecture 251Introduction to Variation Management | Reasons for Variation | Working in Variation Department
Lecture 252Variation Classification | Basis of Classification | US and EU Variation Classification | Other region variation guideline.
Section 11Quality issues, Warning Letter, CAPA and Data Integrity
Lecture 253Data Integrity
Lecture 254Establishment Inspection Report | 483 Observations | USFDA Warning Letter | Handling of FDA inspection | Closing of Warning Letter
Lecture 255Electronic Batch Record for effective compliance management | Key Understanding | Functionalities | Importance in managing data integrity
Lecture 256RTQs | Response to Queries | How to handle Regulatory Queries
Section 12Drug Master File and Site Master File
Lecture 257Key Consideration for Drug Master File Preparation and Submission
Lecture 258Practical Understanding on Drug Master File Preparation and Submission
Lecture 259Associated Learning: Site Master File - Detailed Understanding
Lecture 260DMF Completeness Assessment
Lecture 261Drug Master File - Fees
Lecture 262Drug Master File - Global Perspective [Across Different Regions]
Lecture 263Drug Master File (DMF) Strategy & Regulatory Requirements for Biologics (CMC Focus)
Section 13ASEAN Region - Biologic Regulation, Registration and Strategic Planning
Lecture 264ASEAN Drug Regulations : Comparison Study | Guidelines | Pharmaceutical products Regulatory Submissions | Pharmacopoeia Requirements | stability requirements | Pharmacovigilance | Product labeling | Drug variation information (Prime Session)
Lecture 265Drug Registration and Regulation Singapore | Strategic Pathways for Marketing Authorization | Screening, Evaluation of MA applications | Variations Classifications and Management
Lecture 266Registration and Regulation in Brunei
Lecture 267Registration and Regulation in Cambodia
Section 14African Region - Biologic Regulation, Registration and Strategic Planning
Lecture 268African Continent Overview - Brief introduction to course
Lecture 269African Pharma Market
Lecture 270Drug Registration - African medicines regulatory agencies
Lecture 271Basic Export Requirement for African Countries
Lecture 272Export Documentations & Important Concepts
Lecture 273Nigeria - Drug Registration
Lecture 274Drug Registration in Algeria
Lecture 275Drug Registration in Ethiopia
Lecture 276Drug Registration in Kenya
Lecture 277Drug Registration in Egypt
Lecture 278Drug Registration in Ghana
Lecture 279Drug Registration in Botswana
Lecture 280Drug Registration and Regulation in Uganda
Lecture 281Drug Registration in Zambia
Section 15LATAM Region - Biologic Regulation, Registration and Strategic Planning
Lecture 282Introduction to Latam
Lecture 283Drug Registration and Regulation in Argentina
Lecture 284Drug Registration and Regulation in Bolivia
Lecture 285Drug Registration and Regulation in Brazil
Lecture 286Drug Registration and Regulation in CHILE
Lecture 287Drug Registration and Regulation in Colombia
Lecture 288Drug Registration and Regulation in Mexico
Lecture 289Drug regulation and registration in El Salvador
Lecture 290Central America Drug Regulatory Affairs | Panama, Costa Rica, Guatemala, El Salvador, Honduras, Dominican Republic | RTCA guideline [2022]
Lecture 291Drug regulation and registration in Peru
Lecture 292Drug regulation and registration in Honduras
Lecture 293LATAM Country Clusters & Comparative Regulatory Logic | Wave Filing Strategy
Lecture 294Strategic Understanding on Delta Documentation
Lecture 295Marketing Authorization Framework Across LATAM
Lecture 296LATAM Dossier Structure Differences Matrix
Lecture 297Language Requirements for Latam Filing
Lecture 298ANVISA Regulatory Submission | Delta Packages | CMC | Stability Decision Tree | Case Study
Lecture 299Case Study - ANVISA Submission for generic pharmaceutical | Critical Steps | Pathways | Risk Analysis and Mitigation Strategy
Lecture 300COFEPRIS (Mexico) Regulatory Submission | NCE Pathways | NOM-177 Requirements
Lecture 301Stability Requirements for Pharmaceutical Products in Mexico (COFEPRIS)
Lecture 302LATAM Stability Requirement Comparison (Brazil vs Mexico vs Argentina vs Chile)
Lecture 303Global Stability Program Supporting LATAM Registrations
Lecture 304LATAM Review Test | Check your competency
Lecture 305LATAM Marketing Authorization Simulation
Section 16GCC / Middle East Region - Biologic Regulation, Registration and Strategic Planning
Lecture 306Middle East / MENA / GCC Countries Geographical Orientation
Lecture 307Middle East / MENA / GCC Countries National Regulatory Agencies
Lecture 308GCC Registration Procedure - Centralized and Decentralized Procedure | Detailed understanding on Centralized Registration Process
Lecture 309Drug Registration in Saudi Arabia
Lecture 310Drug Registration in UAE
Lecture 311Drug Registration and Regulatory Strategic Planning for Iran
Lecture 312Drug Registration and Regulatory Strategic Planning for Israel
Lecture 313Drug Registration and Regulatory Strategic Planning for Jordan
Lecture 314Drug Registration and Regulatory Strategic Planning for Iraq
Section 17China - Biologic Regulation, Registration and Strategic Planning
Lecture 315Registration and Regulation in China
Lecture 316New Update: NMPA's the Drug Registration Regulation (DRR) and the Drug Manufacturing Regulation (DMR)
Section 18Russia / EAEU Region - Biologic Regulation, Registration and Strategic Planning
Lecture 317Registration and Submission Strategic Planning for Russia and EAEU region
Lecture 318GMP requirements in Russia
Section 19Japan - Biologic Regulation, Registration and Strategic Planning
Lecture 319Introduction to Japan Drug Regulatory Affairs
Lecture 320Drug Discovery Development to commercialization | PMDA functions | Consultation | Premarket to post market approval
Lecture 321Drug Approval System | GCP | PMDA requirements
Lecture 322New Drug Application | Requirements | Review Process
Lecture 323Generic Drug Application Review and Approval
Lecture 324Marketing Authorization Process for registration of pharmaceutical in Japan
Lecture 325API Registration in Japan | Step By Step Process
Lecture 326Generic Registration | Patent - Patent Term Extension | Exclusivity | Re-examination System | Pediatric Designation | Patent Term Extension Case Studies
Lecture 327Priority Review Application | Criteria | Review Process | Timeline
Lecture 328Orphan Drug Designation in Japan
Lecture 329Japan DMF System | MF filing Process | Key points
Lecture 330Strategic Approval Pathway - Formulation Approval Quoting MF
Lecture 331SAKIGAKE designation
Section 20Introduction to AI in Regulatory Affairs
Lecture 332Introduction to AI
Lecture 333Basics of AI ML DL | Key Differences | Application in industry
Lecture 334Types of AI
Lecture 335AI Project | Overview
Lecture 336Comprehensive Training on AI Project | Managing Stages | AI Iteration
Lecture 337How machine learning
Lecture 338Understanding Regulatory Affairs – Traditional vs. Digital | 2 Case Study
Lecture 339Basics of AI for Regulatory Professionals | Understanding different models used in RA | Case Study | Simulation
Lecture 340AI Terms with Regulatory Significance | Regulatory Applications
Lecture 341NLP in Regulatory Affairs | Conceptual understanding | Usage | NLP in Labeling
Lecture 342Data Grouping with Unsupervised Learning | Case Simulation | Hands on Exercise
Lecture 343Quality Data and Bias | Bias in datasets | Different Types of Bias in Pharma Datasets
Lecture 344AI Data Quality Standard | Checklist
Lecture 345Download AI Data Quality Checklist
Lecture 346Case Study: Accelerated Approval Using Real-World Evidence AI
Lecture 347AI Model for Dossier Submission and Filing - Model Selection | Simulation
Lecture 348AI Technologies in RA
Lecture 349Structured Vs. Unstructured Data | Practical Understanding | Explore Patient Datasets
Lecture 350Sample Data Exercise | Data error | Data Refinement and Cleaning of the data
Section 21AI in Regulatory Authoring and CMC Writing
Lecture 351AI-Powered Regulatory Document Authoring and CMC Writing
Lecture 352AI Tools Comparison - Authoring and CMC Writing (Module 2 & 3)
Lecture 353Tips for Selecting AI Tools (CMC Authoring)
Lecture 354CMC - AI Workflow Checklist | Simulation Based Cases
Lecture 355HITL Regulatory Document Authoring
Lecture 356Confidence Score in Regulatory Authoring | Case Simulation in CMC Authoring
Lecture 357Confidence Scores in Data Extract in Regulatory Writing [Case Simulation]
Section 22eCTD v4.0 Training
Lecture 358eCTDV4.0 Fundamental Understanding | Structures | Key Features
Lecture 359eCTDV4.0 Structure | Lifecycle Management
Lecture 360eCTD Validation | Managing Validation | Tool Types | Types of Error | Validation Error Management
Lecture 361eCTD Validation Tools
Lecture 362eCTD Publishing Cycle
Lecture 363HL7 - Structure and Understanding in the context of eCTD V4.0
Lecture 364Tips and Submission Readiness Checklist
Lecture 365eCTD Submission Checklist Format
Lecture 366Regulatory Publishing Document Control Challenges
Lecture 367Document Control Checklist
Lecture 368Leaf Structure Analysis | Common Error in Leaf Structuring
Lecture 369Formatting Rules Templated and Agency Specification
Lecture 370Versioning for Regulatory Publishing
Lecture 371File Naming Standard
Lecture 372Text Recognition and Optical Character Recognition (OCR)
Lecture 373Versioning File Naming OCR - How they work together
Lecture 374Final Document Assembly
Lecture 375Visual Diagram : eCTD Structure and XML Hierarchy
Lecture 376TOC and CI Management
Lecture 377Initial Submission & Maintenance Submission
Lecture 378Managing Lifecycle Operators - NEW REPLACE DELETE APPEND
Lecture 379eCTD Dossier Lifecycle - Multi Sequence View
Lecture 38010 Year eCTD Lifecycle : Sequence Evolution Diagram
Lecture 381Global Decision Tree - Classifying Post Approval Changes
Lecture 382eCTD Technical Validation | Typical issues | Resolutions
Lecture 383eCTD Validation Readiness Checklist
Lecture 384QC Checklist Design and Pre Submission Review
Lecture 385Submission Gateway | FDA ESG • EMA CESP • Health Canada Portal • PMDA Gateway
Lecture 386Regulatory Publishing Simulation
Lecture 387Pre-Gateway Submission Review Checklist | Post Submission Confirmation
Section 23Risk and Compliance Management
Lecture 388AI and Data Integrity | Regulatory Documentation | Case Based Learning | Understanding Data Integrity Principles | Application and Use Cases
Lecture 389Cases of data breaches with explanation
Lecture 390Case Based Discussion : Data Breach in AI-Assisted CMC Drafting
Section 24Labelling and CCDS Management
Lecture 391CCDS Management
Lecture 392CCDS Management Tools - Native, AI Plus | Key Functionalities
Lecture 393AI Augmented Labelling Compliance System
Lecture 394Label Drift in CCDS Management | Simulation Case Study | AI Based Workflow in Label Drift detection and management
Lecture 395AI Review of Labels, PI and SMPC with help of the Case Based Simulation | 4 Case Simulations
Lecture 396CCDS Management Case Study | Pregnancy Warning Upgrade Case Study
Lecture 397CCDS Management Case Study | Dosage Section Conflict | Case Based Analysis
Lecture 398Centralized Artwork Operation | Mechanism | Operation Step Planning
Lecture 399Case Study on Centralized Artwork Operation [Recall Management]
Lecture 400Artwork Management Terms | Key Understanding on Terminologies | Usage in Artwork Cases
Lecture 401Introduction to Labelling | Regulatory vs Commercial Perspective of Labelling | Labelling Compliance Function
Lecture 402Artwork & Packaging Lifecycle | Artwork Management Lifecycle Workflow
Lecture 403Global Artwork Labelling Framework | 5 Case Simulation
Lecture 404Country-Specific Labelling Requirements
Lecture 405Summary of Product Characteristics (SmPC)
Lecture 406Patient Information Leaflet (PIL)
Lecture 407Summary of Product Characteristics (SmPC) – Review Checklist
Lecture 408Patient Information Leaflet (PIL) – Review Checklist
Lecture 409US Prescribing Information (PI) | Differences with EU SmPC
Lecture 410US Prescribing Information (PI) - Review Checklist
Lecture 411Fundamental Understanding on Medication Guide
Lecture 412Regulatory Decision Flow: When Is a Medication Guide Required? - Step Based Decision Making
Lecture 413Medication Guide - Review Checklist | Inspection Checklist
Lecture 414PI Vs. Medication Guide Comparison
Lecture 415Patient Information Leaflet (PIL) vs Medication Guide
Lecture 416Label Components | Key considerations for effective designing of label
Lecture 417Label Review Checklist
Lecture 418Pharmaceutical Artwork Design Specification Worksheet - Complete Tracker
Lecture 419Color Proofing, Dielines & Version Control
Lecture 420CDR File - Monocarton | Outercarton | Keyline | Design Parameters
Lecture 421Injection Labels - Labels and Cartons
Lecture 422Various Design Component Placement Understanding (Injectables)
Lecture 423Concept of Logo File | Open and Curve File Importance
Lecture 424QC and Proof Reading in Labelling and Artwork
Lecture 425QC and Proofreading Checklist
Lecture 426Template Management and Creative Brief
Lecture 427Pre approval Labelling | ANDA Labelling | ANDA Labelling
Lecture 428Post approval Labelling | PAS | CBE-30 | Annual Reportable Changes
Lecture 429Decision Tree - PAS CBE-0 CBE-30 Annual Reportable Change Determination
Lecture 430Bulk Pack Labelling
Lecture 431Bulk Pack Labelling Checklist
Lecture 432OTC vs Prescription Labelling | Claim Limitations & Consumer Safety Requirements
Lecture 433OTC vs Prescription (Rx) Label Checklist
Lecture 434OTC Approval Matrix
Lecture 435OTC Claim Risk Scoring System
Section 25Evidence Based Decision Making | Combine evidences for decision making | Do we need more evidence?
Lecture 436Evidence Based Decision Making | Combine evidences for decision making | Do we need more evidence?
Lecture 437RWD and RWE | Potential sources of RWE | Traditional RCTs vs. RWE | Case Study - RWE Programs | Influencing HCP decision-making
Lecture 438RWD and RWE in Product Lifecycle Management
Lecture 439RWD and RWE - Fit to use | Assessment
Lecture 440RWD data sources | Different types | Detailed understanding of each class
Lecture 441RWD Study Design
Lecture 442RWE Published Tool | Insights on commonly used tools
Lecture 443Healthcare Reimbursement Models : Value Based Care | Fee for Service (FFS) Model | Other Reimbursement Models
Lecture 444Consensus Narrative Review
Lecture 445Electronic Patient Data | EMR | EHR | Differences | Software architecture and characteristics
Lecture 446Active Surveillance Schemes | Active Case Finding |Sentinel Surveillance | Cohort Studies | Vaccine Safety Surveillance | Pharmacovigilance Programs | Disease Registries |Event Monitoring
Lecture 447RWD Characteristics
Lecture 448RCT vs. RWE Comparison | Case Based Analysis
Lecture 449RCT and RWE Comparison
Section 26Working on Healthcare Datasets
Lecture 450Introduction to Healthcare Datasets
Lecture 451Dataset 1: Claims Data (Insurance)
Lecture 452Dataset 2: Retail Pharmacy Prescription Data
Lecture 453Dataset 3: Longitudinal Patient Data
Lecture 454Characteristics of Different Set of Healthcare Data
Lecture 455Reimbursement and Pricing Datasets
Lecture 456RWE Data Sources & Quality Considerations Checklist | Case Based Analysis
Lecture 457Triangulation and benchmarking | Enhancing Data Validation Through Cross-Referencing
Lecture 458RWD & RWE Case Database
Lecture 459RWE Large Dataset for Data Crunching Exercises |Data cleaning & preprocessing | Comparative Effectiveness Analysis
Section 27AI Tools, Ethics and Future Landscape
Lecture 460AI Reg Tools - Review | Understanding Capabilities
Lecture 461Regulatory Authority View on AI Adoption
Lecture 462Data Sensitivity | Levels | Consequences | Management
Lecture 463Governance Flowchart – AI Tools in GxP Environments
Section 28AI Tools
Lecture 464RA Example - Generalist Vs. Specialist AI Tools
Lecture 465AI Generalist Overview (Life Science Focus)
Lecture 466Horizontal vs Vertical AI Tools
Lecture 467AI Tool Assessment Test
Lecture 468Citation Verification Workflow | AI Tools Management | Hallucination and HITL Action Plan
Section 29Prompt Engineering
Lecture 469Prompt Engineering – Basic Foundations of Prompt Writing | Different Prompt Framework | Case Based Examples
Lecture 470Special Prompting Structure - Case Based Prompt Designing
Lecture 471Special Prompting Structure - Case Based Prompt Designing
Lecture 472Workflow for writing AI Prompts with Life Science Industry Use Cases
Lecture 473PE Parameters | Controlling Creativity, Accuracy, and Output Behavior for Life-Science Applications | Simulation based decision making
Lecture 474How to adjust the parameters | Techniques
Lecture 475Creating A Detailed Regulatory Prompt | Designing Structured Prompt in Code Editor